

- cardiomyopathy patients undergoing heart transplantation. *J Heart Lung Transplant*. 2016;35:625–35.
- [3]. Martínez Bugallo F, Figueira Gonçalves JM, Martín Martínez MD, Díaz Pérez D. Spectrum of Alpha-1 Antitrypsin Deficiency Mutations Detected in Tenerife. *Arch Bronconeumol*. 2017;53:595–6.
 - [4]. Aragón-Sánchez J, García-Rojas A, Lázaro-Martínez JL, Quintana-Marrero Y, Maynar-Moliner M, Rabellino M, et al. Epidemiology of diabetes-related lower extremity amputations in Gran Canaria, Canary Islands (Spain). *Diabetes Res Clin Pract*. 2009;86:e6–84.
 - [5]. Cabrera López C, Juliá Serdá G, Cabrera Lacalzada C, Martín Medina A, Gullón Blanco JA, García Bello MA, et al. Prevalence of chronic obstructive pulmonary disease in the Canary Islands. *Arch Bronconeumol*. 2014;50:272–7.
 - [6]. Figueira Gonçalves JM, Golpe R, García Bello MA, García-Talavera I, Castro Añón O. Comparison of the prognostic capability of two comorbidity indices in patients with chronic obstructive pulmonary disease, in real-life clinical practice. *Clin Respir J*. 2019;13:404–7.
 - [7]. Figueira Gonçalves JM, Dorta Sánchez R, Rodríguez Pérez MDC, Viña Manrique P, Díaz Pérez D, Guzmán Saenz C, et al. Cardiovascular comorbidity in patients with chronic obstructive pulmonary disease in the Canary Islands (CCECAN study). *Clin Investig Arterioscler*. 2017;29:149–56.
 - [8]. Figueira Gonçalves JM, Martín Martínez MD, Pérez Méndez LI, García Bello MA, García-Talavera I, Hernández SG, et al. Health Status in Patients with COPD According to GOLD 2017 Classification: Use of the COMCOLD Score in Routine Clinical Practice. *COPD*. 2018;6:1–8.
 - [9]. Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, et al. The revised GOLD 2017 COPD categorization in relation to comorbidities. *Respir Med*. 2018;134:79–85.
 - [10]. Figueira Gonçalves JM, García Bello MA, Martín Martínez MD, Pérez Méndez LI, García-Talavera I, García Hernández S, et al. The COPD comorbidity in the light of the degree of dyspnea and risk of exacerbation. *COPD*. 2019;16:104–7.
 - [11]. Miller J, Edwards LD, Agustí A, Bakke P, Calverley PM, Celli B, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. *Respir Med*. 2013;107:1376–84.
 - [12]. Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. *Am J Respir Crit Care Med*. 2018;198:51–7.
 - [13]. Figueira Gonçalves JM, García Bello MA, Bethencourt Martín N, Díaz Pérez D, Pérez-Méndez LI. Impact of 13-valent pneumococcal conjugate polysaccharide vaccination on severe exacerbations in patients with chronic obstructive pulmonary disease and established cardiovascular disease. *Eur J Intern Med*. 2019;63:e14–6.
 - [14]. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2012;186:155–61.
 - [15]. Figueira Gonçalves JM, García Bello MA, Martín Martínez MD, García-Talavera I, Golpe R. Can the COPD-comorbidity index be applied to all outpatients with chronic obstructive pulmonary disease? A Single-center Analysis. *Arch Bronconeumol*. 2019, pii: S0300-2896(19)30212-1.

Figueira Gonçalves JM*

Servicio de Neumología y Cirugía Torácica, Hospital Universitario Nuestra Señora de la Candelaria (HUNSC), Santa Cruz de Tenerife, Spain

Corresponding author at: Camino Margallo nº 29 Vivienda 4 CP: 38206 San Cristóbal de la Laguna (Santa Cruz de Tenerife), Santa Cruz de Tenerife, Spain.

E-mail address: juanmarcofigueira@gmail.com

<https://doi.org/10.1016/j.arbr.2019.07.004>

1579-2129/ © 2019 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Cryptococcus neoformans pleuritis in an immunocompetent patient[☆]



Pleuritis por *Cryptococcus neoformans* en paciente inmunocompetente

To the Editor:

The genus *Cryptococcus* includes different species of encapsulated yeast fungi, of which only *C. neoformans* is considered a human pathogen. Its polysaccharide capsule confers virulence by protecting it from phagocytosis and complement activity. Four serotypes within this species have been described – A, B, C, and D – depending on the components of the capsule. Serotypes A and D are identified as *C. neoformans* var. *neoformans*, and antigens B and C as *C. neoformans* var. *gattii*. The 2 varieties differ both in their pathogenesis and their geographical distribution. *C. neoformans* var. *neoformans* is distributed worldwide and is associated with infections in immunocompromised patients, while *C. neoformans* var. *gattii* has been associated with infections in immunocompetent patients, and its distribution is more restricted to tropical and subtropical countries.¹

C. neoformans var. *neoformans* can affect any individual, although it is more common in patients with a predisposing factor (HIV infection, use of immunosuppressive drugs, connective tissue disease, cirrhosis, etc.).²

Despite the fact that the pigeon feces are the most important source of infection, these animals do not suffer from the disease. Humans acquire *Cryptococcus* infection by the respiratory route, and transmission from person to person has not been proven.

[☆] Please cite this article as: Rodríguez-Álvarez A, Fernández-Rial Á, Pérez-López A, Pita J. Pleuritis por *Cryptococcus neoformans* en paciente inmunocompetente. *Arch Bronconeumol*. 2020;56:59–60.

Although the infection tends to enter via the airways, pulmonary involvement is rare, while the most common presentation is neurological. Pulmonary lesions caused by *Cryptococcus* vary, and include nodules, masses, interstitial infiltrates, alveolar consolidation, and lymphadenopathy.^{3,4} Pleural effusion, either isolated or associated with pulmonary disease is a rare manifestation.^{2–6}

We describe a case of pleuritis caused by *C. neoformans* in an immunocompetent patient.

Our patient was a 78-year-old man with a history of chronic kidney disease stage 3a, permanent atrial fibrillation, congestive heart failure with preserved ejection fraction, alcoholic liver disease, and chronic obstructive pulmonary disease/sleep apnea hypopnea syndrome overlap (COPD + SAHS) receiving treatment with CPAP. He attended our clinic due to a 4 or 5-day-history of sudden onset right pleuritic pain, accompanied by increased dyspnea, cough with expectoration of mucus, and low-grade fever in the afternoon. His general status on physical examination was good, with blood pressure 139/68 mmHg, heart rate 83 bpm, axillary temperature 37.5 °C, SatO₂ 95 % baseline. Mobile right axillary lymphadenopathies were detected, with no palpable lymphadenopathies in other territories. Arrhythmias were heard on cardiac auscultation, and pulmonary auscultation revealed reduced breath sounds in the right lung base with bilateral rhonchi; no other significant findings were detected on physical examination.

Clinical laboratory tests were significant for mild anemia and raised inflammatory markers. Chest radiography revealed right pleural effusion.

A diagnostic thoracentesis was performed, and the drained fluid showed biochemical characteristics of exudate: pH 7.45, glucose 121 mg/dl, protein 4.1 g/dl, ADA 24.7 U/l, erythrocytes 25,200 μl, nucleated cells 3100 μl (polymorphonuclear 39 %, lymphocytes 23 %, macrophages 38 %, and reactive mesothelial cells). Pleural fluid, sputum, and blood were collected and sent for culture.

Diuretic treatment with furosemide was intensified and empiric antibiotic coverage started with ceftriaxone. On day 4 of admission,




Fig. 1. Computed tomography showing right pleural effusion associated with loss of volume.

the patient was afebrile, with negative water balance and improved pleuritic pain and dyspnea. At this time, the microbiology laboratory reported isolation of yeasts in pleural fluid, so the thoracentesis was repeated, and blood cultures were collected again. A back of the eye study was normal, and HIV serology was negative. Treatment started with fluconazole.

Chest CT scan revealed right free-flowing pleural effusion 5 cm thick, causing passive atelectasis of the right lower lobe (Fig. 1), with no other changes.

Blood and sputum cultures were negative. The yeast was identified as *C. neoformans* by 2 different microbiological methods: the VITEK system® 2 (Biomérieux, Marcy l'Etoile, France) and MALDI-TOF mass spectrometry (Bruker). The yeast was also isolated in the second pleural fluid culture. Testing for cryptococcal antigen in serum was also requested, which was negative.

Treatment was switched to voriconazole 200 mg every 12 h and thoracentesis was performed for drainage, with subsequent resolution of the effusion. Treatment continued for a month on an outpatient basis. After completion of the antifungal treatment, the patient attended a subsequent check-up in the outpatient clinic, and had returned to baseline.

C. neoformans pleuritis is a rare entity, which occurs mainly in immunosuppressed patients. In a recent review² that included 25 cases of cryptococcal pleural effusion, 20 of the 25 patients had some type of immunosuppression; among the most common predisposing factors were HIV infection (7 cases), solid organ transplant (5 cases), or tumor disease (4 cases). In an earlier review⁶ of 30 cases, underlying disease was documented in 17 cases, while 10 had no predisposing factor. In that cohort, most patients with cryptococcal pleural effusion had disseminated cryptococcosis, whereas localized chest infection was more common in immunocompetent patients.⁶ Our patient, despite a previous diagnosis of alcoholic liver disease, presented no clinical, laboratory, or imaging data suggestive of advanced liver disease, which as we mentioned is one of the factors often associated with this infection.

Cryptococcal pleuritis can, therefore, occur in isolation, in association with lung consolidation or not, or in the context of disseminated cryptococcosis. For the diagnosis of cryptococcal pleural effusion, the organism must be isolated in a culture

of pleural fluid or pleural biopsy.⁴ In the event of disseminated cryptococcal disease, the detection of cryptococcal antigen in the blood could be useful. Our patient had isolated effusion due to *C. neoformans* with no pulmonary consolidation (ruled out on CT) or dissemination to other organs (which might explain why the cryptococcal antigen in serum was negative). Although *Cryptococcus* was isolated in our patient from 2 cultures of pleural fluid, cultures can be sometimes negative, given the small amount of inoculum present in the pleural fluid.^{3,5} If the culture is negative, it may be helpful to test for cryptococcal antigen in pleural fluid (not carried out in our case), since the effusion is simply an inflammatory response to cryptococcal antigen.⁵

The mechanism of entry of the infection to the pleural space is usually by the pulmonary route, although the pleura could also be accessed by hematogenous spread. We believe the first route is the most likely in our case, and we speculate that his CPAP may possibly have been involved in the pathogenesis of this infection.⁷ In this respect, we cultured the tubing and the humidifying fluid, which were negative, although these were sampled on Day 6 of admission, after the fluid had been changed, so we could not confirm this hypothesis.

In conclusion, cryptococcal pleuritis is a rare entity which can occur in immunocompetent subjects, and one that should be taken into account in the differential diagnosis of pleural effusion in this type of patients. Given the suspicion that the source of infection in our patient could have been the CPAP, users of these devices must be made acutely aware of the importance of their appropriate use and disinfection because of the serious consequences that can result from their incorrect use.

References

1. Brizendine KD, Baddley JW, Pappas PG. Pulmonary cryptococcosis. *Semin Respir Crit Care Med.* 2011;32:727–34.
2. Swan CD, Gottlieb T. *Cryptococcus neoformans* empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature. *BMJ Case Rep.* 2018;2018, pii: bcr-2018-224786.
3. Chen M, Wang X, Yu X, Dai C, Chen D, Yu C, et al. Pleural effusion as the initial clinical presentation in disseminated cryptococcosis and fungaemia: an unusual manifestation and a literature review. *BMC Infect.* 2015;15:385.

- Izumikawa K, Zhao Y, Motoshima K, Takazono T, Saijo T, Kurihara S, et al. A case of pulmonary cryptococcosis followed by pleuritis in an apparently immunocompetent patient during fluconazole treatment. *Med Mycol*. 2008;46:595–9.
- Wee ACR, Seet JE, Venkatalacham J, Tan SK. Cryptococcal pleural infection in a recurrent pleural effusion: a case report. *Respirol Case Rep*. 2018;6:e00294.
- Young EJ, Hirsh DD, Fainstein V, Williams TW. Pleural effusions due to *Cryptococcus neoformans*: a review of the literature and report of two cases with cryptococcal antigen determinations. *Am Rev Respir Dis*. 1980;121:743–7.
- Chin CJ, George C, Lannigan R, Rotenberg BW. Association of CPAP bacterial colonization with chronic rhinosinusitis. *J Clin Sleep Med*. 2013;9:747–50.

Ana Rodríguez-Álvarez^{a,*}, Álvaro Fernández-Rial^a,
Antía Pérez-López^a, Julia Pita^b

^a Servicio de Medicina Interna, Hospital Universitario Lucus Augusti, Lugo, Spain

^b Servicio de Microbiología Clínica, Hospital Universitario Lucus Augusti, Lugo, Spain

Corresponding author.

E-mail address: ana.rodriguez.alvarez@sergas.es

(A. Rodríguez-Álvarez).

<https://doi.org/10.1016/j.arbr.2019.11.003>

1579-2129/ © 2019 The

Author(s). Published by Elsevier España, S.L.U. on behalf of SEPAR. All rights reserved.

P.TYR1381X: Are We Facing a New Mutation of CFTR in a Patient With Severe Cystic Fibrosis?



P.TYR1381X: ¿Nos enfrentamos a una nueva mutación de CFTR en un paciente con fibrosis quística grave?

Dear Editor,

Cystic fibrosis (CF) is the most frequent genetic disorder in the Caucasian race produced by the cystic fibrosis transmembrane conductance regulator (CFTR) gene disturbance. This gene, located on the long arm of chromosome 7, was first discovered by Andersen in 1938, although it was not until 1989 when it was identified as causing CF. This disease is transmitted in an autosomal recessive Mendelian inheritance pattern. Although it can be expressed phenotypically in different ways, it affects the exocrine epithelial cells of the respiratory system, the pancreas, the bile ducts, the sweat glands and the genitourinary system.¹

In Spain, a decrease in the incidence of CF after the implantation of neonatal screening is recognized. However, the prevalence has increased^{2,3} in relation to the greater survival of these patients due to the improvement in the quality of care and the new therapeutic strategies making a disease that was initially considered pediatric^{4,5} become chronic.

The allelic heterogeneity of CFTR gene was described in the 1990s⁶ and it has recently been shown that the complexity of the mutation spectrum is greater than previously known.⁷

Alonso et al. managed to identify in Spain a total of 121 mutations of the CFTR gene, which represents 96% of the 1,954 Spanish alleles studied. Twelve of them presented frequencies higher than 1%, the most frequent being p.Phe508del (also known as F508del). Those that have a frequency lower than 0.5% are considered rare mutations⁷. To date, there is a global registry of CFTR mutations in the CF Mutation Database (CFTR1)⁸ and in the Clinical and Functional Translation of CFTR database (CFTR2) with constant updating,⁹ although some very rare and of uncertain clinical significance mutations continue to emerge. The identification of these gene disturbances and the phenotypic characterization of these patients allow us to know better the functional importance of the CFTR gene. Because of this, homozygous patients are required for these specific mutations, in which all the phenotypic expression can be attributed to that specific genetic alteration although unfortunately they are not usually prevalent.

We present the case of a 19-year-old Caucasian male homozygous for the p.Tyr1381X mutation (legacy name: Y1381X; DNAC: c.4143C>A). It is a mutation of synthesis defect (type I) whose functional alteration resulting is the absence of protein synthesis and characterized by the substitution of the amino acid tyrosine at position 1381 of CFTR by a termination codon.

He was diagnosed with CF at 15 months old after admission for recurrent infections, diarrhoea and weight loss. The analysis of sweat test revealed that the concentration of chloride was 141 and 145 mEq/L. The first genetic analysis performed on him after diagnosis was negative but it was used a basic panel of mutations. A most advanced genetic study was carried out at 2015 and characterized the real mutation of which up to that moment only one case had been registered in CFTR1.⁸ He was a full-term infant born before the CF neonatal screening implant. His birth weight was 2.9 kg, birth length 48 cm. Parental consanguinity was ruled out. His parents and his elder sister were carriers of this mutation but they were asymptomatic.

Until he was 15 years old the follow-up was performed by paediatrics. When he arrived at the Pulmonology Department he presented respiratory and digestive affection, CF-associated arthritis and growth retardation. He presented chronic bronchial infection (CBI) by methicillin-sensitive *Staphylococcus aureus* (MSSA) since 14 years old without clinical repercussions. His treatment to date was: nebulized dornase alfa and hypertonic saline with hyaluronic acid (2.5 mg/24 h and 5 ml/12 h, respectively), budesonide/formoterol (160/4.5 µg/12 h), salbutamol (if need), azithromycin (250 mg three times per week) and respiratory physiotherapy. He presented CBI by *Pseudomonas aeruginosa* (PA) since 16 years old so treatment was started with nebulized colistimethate sodium (1 MIU/12 h) and the PA infection was eradicated after two years. This therapy was discontinued in that moment. The patient did not have PA infections again; however, the CBI by MSSA persisted in time until the present.

Nowadays he presents a rapidly progressive clinical deterioration, highlighting recurrent infections. Last year he had a moderate exacerbation that was managed ambulatory with oral antibiotics and two severe exacerbations that required hospital admission due to respiratory failure. Due to respiratory deterioration, nebulized treatment with vancomycin was started for MSSA. Thoracic CT showed generalized cystic bronchiectasis. The respiratory deterioration has led to the request for evaluation of lung transplantation being currently on the waiting list.

Other comorbidities are severe pancreatic insufficiency (pancreatic gland atrophy and diffuse fatty replacement), iron-deficiency anaemia and acute severe malnutrition in the context of recent exacerbations.

The lung function, weight, height and CBI evolution is summarized in Table 1.

Despite genetic counselling, progress in the detection methods of mutations causing CF and implantation of neonatal screening in recent decades, there is still a small percentage of very rare mutations which are being identified and whose phenotypic behaviour is unknown. Its recognition allows us to advance in the study of this disease, especially in those cases of homozygous since its